Breaking News, Collaborations & Alliances

CSL Enters Strategic Collaboration with VarmX for VMX-C001

CSL will pay VarmX shareholders $117 million upfront for an exclusive option to acquire the company.

Author Image

By: Charlie Sternberg

Associate Editor

CSL Limited has entered into an agreement with Dutch biotech company, VarmX, to support the development of its lead asset, VMX-C001, a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs. CSL has also entered into an exclusive option agreement with VarmX shareholders to acquire all issued and outstanding shares of the company. Under the terms of the strategic collaboration agreement, CSL will fully fund Varm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters